Hugh Alsop is an accomplished pharmaceutical and biotechnology executive with over 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. He has commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Mr Alsop has an enviable track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products. He was chief executive of Hatchtech which he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as director of dusiness development at Acrux, Mr Alsop was a key member of the team that secured, at the time, the single largest product licensing deal by an Australian biotech company when Acrux licensed its testosterone product Axiron™ to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties. Before working with Acrux, he worked at Sigma Pharmaceuticals and Faulding Pharmaceuticals in business development and manufacturing related roles. Mr Alsop holds a Bachelor of Science (Honours) in Chemistry from the University of Melbourne and an MBA from the Melbourne Business School.
